The aim of this prospective, observational study was to determine the effectiveness of sublingual and topical compounded bio-identical hormone replacement therapy (BHRT) in treating vasomotor, mood and other quality of life symptoms in post-menopausal women. The women in the study were allocated to receive sublingual or topical BHRT, with 100% of the sublingual group and 99% of the topical group receiving progesterone as part of their BHRT regimen. Overall, the researchers found that women who received BHRT in a sublingual form experienced statistically significant reductions in menopausal symptoms, mood symptoms, vasomotor symptoms, sleep disturbances, memory loss, fatigue and loss of libido at one to three-month follow-ups compared to baseline. The women in the topical BHRT group experienced some improvements in moderate to severe menopausal symptoms, and this type of therapy resulted in statistically significant reductions in mood swings, irritability and night sweats only.